As the activation of Akt by HER2/PI3K confers chemoresistance in breast cancer, these data support the potential usefulness of combining SZ-685C with other therapeutics in combating MDR in breast cancer chemotherapy [71]. This evidence concerns the gene ERBB2 and breast carcinoma.